Seawolf Therapeutics emerged from stealth with $100 million in new financing aimed at building non-viral DNA delivery. The San Diego startup is developing its TRIDENT platform, which packages engineered DNA into lipid nanoparticles for delivery to cells and longer-lasting expression, with an emphasis on redosing—an area where many viral vectors face limitations. The debut also includes a partnership with Sanofi, structured as a multi-target collaboration for therapies in bleeding disorders and other indications. Investors in the round included Versant Ventures, with participation from Eli Lilly and others, positioning Seawolf for lead-program progression and platform scale-up. The company’s plan highlights a competitive push toward repeat-dosing gene delivery using LNP chemistry rather than viral capsids. In parallel, the investment underscores ongoing interest from major pharma in non-viral modalities for therapeutic DNA payloads and metabolic disease targets.